Megna Michael R's Form 4 filing
Kiniksa Pharmaceuticals International, plc (KNSA) · filed May 9, 2025
- Accession no.
- 0001415889-25-012532
- Filed
- May 9, 2025
- Trade date
- May 7, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $471.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Megna Michael RCIK 0001464583 | Officer (CHIEF ACCOUNTING OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 7, 2025 | Class A Ordinary Share | MOption exerciseAcquired | +229 | $8.83 | +$2,022.07 | 32,775 | Direct | |
| May 7, 2025 | Class A Ordinary Share | MOption exerciseAcquired | +2,998 | $15.50 | +$46,469 | 35,773 | Direct | |
| May 7, 2025 | Class A Ordinary Share | MOption exerciseAcquired | +14,420 | $11.97 | +$172,607.4 | 50,193 | Direct | |
| May 7, 2025 | Class A Ordinary Share | SSaleDisposed | −17,647 | $26.69 | −$470,998.43 | 32,546 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 7, 2025 | Class A Ordinary Share | MOption exerciseDisposed | −229 | $0.00 | $0 | 0 | Direct | |
| May 7, 2025 | Class A Ordinary Share | MOption exerciseDisposed | −2,998 | $0.00 | $0 | 16,002 | Direct | |
| May 7, 2025 | Class A Ordinary Share | MOption exerciseDisposed | −14,420 | $0.00 | $0 | 17,040 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.